News: Development of inactivated SARS-CoV-2 vaccines - FAIS Africa

April 26, 2020 | Development of inactivated SARS-CoV-2 vaccines |

COVID-19 and SARS-CoV-2 update from

Disclaimer: This article is a summary of a pre-print by Gao et al., published on BioRxiv. This research article at the time of writing this summary has not been peer-reviewed.

In this pre-peer reviewed article, the authors report on the development of a purified inactivated SARS-CoV-2 vaccine candidate which they show induces virus-specific moderately broadly neutralizing antibodies in mice, rats and non-human primates. A SARS-CoV-2 coronavirus, isolated from a COVID-19 infected patient, was cultured and inactivated with β-propiolactone for 24 hours. After purification and mixing with an Al(OH)3 adjuvant, three intramuscular immunizations were given to macaques at two doses (3 and 6ug/dose). The vaccine was found to provide partial or complete protection (at the higher dose) when subsequently challenged with SARS-CoV-2/.

Article: Gao et al., Rapid development of an inactivated vaccine for SARS-CoV-2. BioRxiv Pre-print